SCHEMBL5680826

SCHEMBL5680826

CCOC(=O)c1cnn(-c2ccc(Cl)cc2)c1C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.60
RAB9A P51151 3/20 0.60
SMN1; SMN2 Q16637 5/20 0.59
TSHR P16473 1/20 0.59
MAPK1 P28482 1/20 0.58
HTT P42858 1/20 0.57
KMT2A Q03164 4/20 0.56
HPGD P15428 1/20 0.56
LMNA P02545 2/20 0.55
MAPT P10636 2/20 0.55
MEN1 O00255 2/20 0.55
GAA P10253 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
NPC1 O15118 2/20 0.55
POLB P06746 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.52
P2RY12 Q9H244 1/20 0.51
CCR1 P32246 1/20 0.51
DRD2 P14416 1/20 0.51
DRD4 P21917 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6405411 0.89 ALDH1A1 (0.60) ALDH1A1RAB9ASMN1; SMN2TSHRMAPK1
SCHEMBL8342039 0.87 HTT (0.58) ALDH1A1RAB9ASMN1; SMN2TSHRMAPK1
SCHEMBL15167569 0.87 ALDH1A1 (0.61) ALDH1A1RAB9ASMN1; SMN2TSHRMAPK1
SCHEMBL6403552 0.86 ALDH1A1 (0.57) ALDH1A1RAB9ASMN1; SMN2TSHRMAPK1
SCHEMBL6527991 0.86 ALDH1A1 (0.81) ALDH1A1RAB9ASMN1; SMN2TSHRHTT
SCHEMBL31636462 0.86 ALDH1A1 (0.57) ALDH1A1RAB9ASMN1; SMN2TSHRMAPK1
SCHEMBL6052641 0.86 ALDH1A1 (0.60) ALDH1A1RAB9ASMN1; SMN2TSHRHPGD
SCHEMBL8339357 0.86 ALDH1A1 (0.60) ALDH1A1RAB9ASMN1; SMN2TSHRMAPK1
SCHEMBL1065124 0.86 ALDH1A1 (0.75) ALDH1A1RAB9ASMN1; SMN2TSHRMAPK1
SCHEMBL15167344 0.86 GPR35 (0.56) RAB9ASMN1; SMN2TSHRMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-11130753-A None JP disclosed
WO-2025137158-A1 DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2025-06-26 WO disclosed
EP-4565225-A2 PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM The Johns Hopkins University (US) 2025-06-11 EP disclosed
WO-2024030535-A2 PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM THE JOHNS HOPKINS UNIVERSITY (US) 2024-02-08 WO disclosed
EP-4288440-A1 PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS The Johns Hopkins University (US) 2023-12-13 EP disclosed
WO-2014181287-A1 HETEROCYCLYL COMPOUNDS AND USES THEREOF Piramal Enterprises Limited (IN) 2014-11-13 WO disclosed
EP-1620405-A2 PYRAZOLE-AMIDES AND SULFONAMIDES AS SODIUM CHANNEL MODULATORS Abbott Laboratories (US) 2006-02-01 EP disclosed
US-20050020564-A1 Pyrazole-amides and sulfonamides as sodium channel modulators ABBOTT LABORATORIES 2005-01-27 US disclosed
WO-2004099154-A2 PYRAZOLE-AMIDES AND SULFONAMIDES AS SODIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2004-11-18 WO disclosed
US-20040220170-A1 Pyrazole-amides and sulfonamides as sodium channel modulators ABBOTT LABORATORIES 2004-11-04 US disclosed
US-5990139-A 2,5-DIOXO-4-(PYRIDYL OR PHENYL-(N-HETEROCYCLE(C4N,C3N2))-ALKYLENOXY-(1,4-PHENYLENE) -)THIADIAZOLIDINES; ANTIDIABETIC AND -LIPEMIC AGENTS; SIDE EFFECT REDUCTION TAIHO PHARMACEUTICAL CO., LTD. (JP) 1999-11-23 US disclosed
JP-H11130753-A PHENYLCARBOXYLIC DERIVATIVE TAIHO YAKUHIN KOGYO KK 1999-05-18 JP disclosed
US-5888941-A Carbozamides with antifungal activity J. URIACH & CIA. S.A. (ES) 1999-03-30 US disclosed
EP-0783502-A1 NEW CARBOXAMIDES WITH ANTIFUNGAL ACTIVITY J. URIACH & CIA. S.A. (ES) 1997-07-16 EP disclosed
WO-1997005131-A1 NEW CARBOXAMIDES WITH ANTIFUNGAL ACTIVITY J. URIACH & CIA. S.A. (ES) 1997-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020564-A1 Pyrazole-amides and sulfonamides as sodium channel modulators SCN3A, KCNN3, TRPV3 ALDH1A1 3384/4885RAB9A 3662/4885SMN1; SMN2 395/4885
US-20040220170-A1 Pyrazole-amides and sulfonamides as sodium channel modulators SCN3A, KCNN3, TRPV3 ALDH1A1 3384/4885RAB9A 3662/4885SMN1; SMN2 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.